China's Assisted Reproductive Technology Management Measures: Policy Interpretation and Clinical Application Standards Guide

Opening: Doctor's Clinical Decision-Making Logic

I. What Exactly Do the Management Measures Govern? — Core Answers

The Management Measures for Human Assisted Reproductive Technology (hereinafter referred to as the "Measures") are the administrative regulations that all assisted reproductive technology institutions within China must comply with. They establish a management framework from four levels:

• Institutional Access — Only medical institutions approved by health administrative departments at the provincial level or above can carry out assisted reproductive technology, and they undergo re-inspection every two years.
• Technical Scope — Clearly defines the indications and contraindications for artificial insemination, in vitro fertilization-embryo transfer and its derivative technologies (such as intracytoplasmic sperm injection, preimplantation genetic testing).
• Ethical and Legal Red Lines — Prohibits surrogacy, prohibits the illegal trading of gametes, zygotes, and embryos, and strictly implements the principles of informed consent and mutual anonymity.
• Quality and Follow-up — Requires the establishment of technical files, a pregnancy follow-up rate of no less than 90%, and long-term tracking of offspring health.

Simply put, the Measures answer the four basic questions: "Who can do it, what can be done, what cannot be done, and how to manage it." The operational standards of any legitimate reproductive center are detailed within this framework.

II. How Clinicians View the Implementation of the Management Measures

In practice, doctors most frequently refer to the Measures to manage three key points:

• Are the indications clear? Conditions such as female tubal blockage, severe male oligoasthenospermia, or ovulation disorders unresponsive to more than 3 cycles of ovulation induction must have clear medical indications.
• Are contraindications excluded? Uncontrolled endocrine diseases, malignant tumors, acute infections, severe mental disorders, etc., are all situations for postponement or contraindication.
• Is the ethical review complete? All steps involving donor sperm, donor eggs, embryo cryopreservation, or disposal must have a signed written informed consent form from the patient and be filed with the ethics committee.

III. Differences in the Application of Management Measures by Age

The Measures themselves do not have a "one-size-fits-all" age limit, but the supporting Technical Standards for Human Assisted Reproductive Technology provide clear clinical guidance on age factors, directly affecting the treatment path:

Behind these age stratifications lies the dual consideration of the management measures for "medical safety" and "technical effectiveness." The older the age, the higher the pregnancy risk, and the greater the demands on the institution's technical capability and follow-up management.

IV. Differences in Implementation Across Medical Institutions

As of 2025, there are over 500 approved reproductive centers nationwide, but there are significant differences in their technical access levels:

• Level A (Comprehensive Technical Access): Can perform all technologies including artificial insemination, IVF, ICSI, PGT, donor sperm/eggs. Usually provincial reproductive medicine centers or university-affiliated hospitals.
• Level B (Conventional Technical Access): Can perform artificial insemination, IVF/ICSI, but lacks PGT qualifications. Cases requiring genetic testing must be referred to higher-level centers.
• Level C (Single Technical Access): Only approved for artificial insemination (husband sperm or donor sperm), cannot perform in vitro fertilization.

When choosing an institution, patients should first check the scope of the institution's "Assisted Reproductive Technology Practice License" on the National Health Commission's official website or provincial health commission announcements. Some centers, although well-known, may not yet have obtained PGT or donor sperm qualifications, a detail that is easily overlooked.

V. Most Easily Overlooked Details

Based on experience from daily consultations and quality control inspections, the following three details are often underestimated by patients and even some medical staff:

• Timing of Signing the Informed Consent Form: According to regulations, all operations involving gametes/embryos (including freezing, thawing, disposal, donation) must have a separate consent form signed before the procedure; they cannot be "signed off in one go." For example, after the embryo cryopreservation period expires, if the patient does not renew the preservation consent form, the hospital must handle it according to the ethical process. This should be clearly communicated during the initial consultation.
• Mutual Anonymity Requirement for Gamete Donation: Permanent mutual anonymity is maintained between the sperm/egg donor and the recipient. The medical team must also manage the identity information of both parties separately. This means patients cannot know the donor's name, address, or other personal information, only basic phenotypic characteristics (e.g., blood type, skin color, height).
• Disposal of "Surplus" Embryos: Many couples only focus on the transfer stage and do not plan in advance for "how to handle surplus embryos." The management measures clearly require patients to make a written choice before treatment regarding options such as embryo cryopreservation, donation for scientific research, or disposal. If no choice is made, the hospital has no right to dispose of them unilaterally.

VI. Actual Process: From Initial Consultation to Transfer

According to the Measures and their implementation rules, a standard IVF cycle process can be divided into the following stages:

1. Initial Consultation and Assessment (Outpatient): Medical history collection, physical examination, fertility assessment for both partners (female AMH, antral follicle count, male semen analysis). Confirm that indications are met and contraindications are absent.
2. Supplementary Examinations (1-2 weeks): Infectious disease screening (Hepatitis B, Hepatitis C, HIV, Syphilis), chromosome karyotype analysis, TORCH screening, coagulation function, thyroid function, etc.
3. Ethical Review and Informed Consent (1-3 working days): The hospital's ethics committee reviews the case, focusing on indications, contraindications, and the completeness of the informed consent form. Formal filing occurs after approval.
4. Protocol Formulation and Ovarian Stimulation (10-14 days): Choose an ovarian stimulation protocol (antagonist protocol, long protocol, PPOS protocol, etc.) based on the woman's age, ovarian reserve, and previous treatment response.
5. Egg Retrieval Surgery (30 minutes): Transvaginal ultrasound-guided follicle aspiration. Patients can be discharged after 1-2 hours of observation if no abnormalities occur.
6. Embryo Culture and Transfer (3-6 days): Embryo transfer is performed on day 3 or day 5-6 after egg retrieval. Surplus embryos are cryopreserved.
7. Luteal Phase Support and Pregnancy Test (12-14 days post-transfer): Use progesterone and other medications to support the endometrium. A blood hCG test is performed 12-14 days after transfer to confirm pregnancy.
8. Follow-up Management: After pregnancy confirmation, the patient is transferred to obstetrics for filing. The reproductive center must track the pregnancy outcome until delivery and record the health status of the offspring.

VII. Timeline: How Long Does It Take from Preparation to Completion?

From the first visit to pregnancy confirmation, it takes approximately 2-3 months if all goes smoothly. If it involves waiting for donor sperm/egg resources or requires PGT, the time extends to 4-6 months or even longer.

VIII. Frequently Asked Questions

Below are the most common questions patients ask in daily outpatient clinics regarding the management measures:

• Q: Is IVF covered by medical insurance? A: As of 2025, some regions such as Beijing, Shanghai, Zhejiang, and Guangdong have included certain assisted reproductive services (e.g., egg retrieval, embryo culture, transfer) in the scope of medical insurance reimbursement. However, reimbursement rates and scopes vary by region, and the management measures themselves do not address insurance policies. You need to check the latest directory from your local medical insurance bureau.
• Q: How are frozen embryos handled in case of divorce? A: According to ethical principles and the terms of the informed consent form, if the divorced couple cannot reach an agreement on embryo disposal, the hospital has no right to unilaterally destroy or transfer them. Typically, a jointly signed written opinion is required. It is recommended to sign a detailed embryo disposal authorization form before treatment.
• Q: How long can embryos be frozen? A: The management measures do not set a hard upper limit for the cryopreservation period, but individual reproductive centers usually set it at 5-10 years. Before the period expires, the preservation consent form must be renewed and the storage fee paid. If not renewed by the deadline, the embryos will be handled according to the ethical procedure.
• Q: Can IVF be performed without a marriage certificate? A: According to the Measures, the implementation of assisted reproductive technology must comply with the national family planning policy. Currently, legitimate reproductive centers in China require both partners to provide ID cards, marriage certificates, and proof of fertility (or proof of compliance with fertility policies). Unmarried couples or those not meeting fertility policies cannot legally receive assisted reproductive technology in China.
• Q: What should out-of-town patients prepare for a visit? A: In addition to the documents mentioned above, it is recommended to bring all previous examination reports and surgical records (especially hysterosalpingography, hysteroscopy, and laparoscopy records). Results from other hospitals are mutually recognized within their validity period (usually 1 year), but some items like infectious disease screening and chromosome karyotyping may need to be re-verified at the admitting hospital.

IX. Handling Special Situations

In clinical practice, some situations require handling according to the special provisions of the Measures:

• Male Azoospermia (Obstructive or Non-obstructive): If donor sperm is needed, it must be confirmed that the male has irreversible azoospermia, and both partners must sign the donor sperm informed consent form. The donor sperm source must come from an approved human sperm bank; self-sourcing of sperm donors is not permitted.
• Recurrent Implantation Failure (RIF): If pregnancy has not occurred after 3 consecutive transfer cycles or a cumulative transfer of ≥ 4 good-quality embryos, a re-evaluation of endometrial receptivity, immune factors, and embryo chromosomes is necessary. PGT-A or endometrial microbiome testing may be required. These advanced tests must be performed at centers with the corresponding qualifications.
• High Risk of Ovarian Hyperstimulation Syndrome (OHSS): For patients with PCOS who have AMH > 5 ng/mL and AFC > 20, the Measures require the use of low-dose ovarian stimulation protocols or a freeze-all embryo strategy to reduce the incidence of OHSS. This is a mandatory quality control indicator in clinical practice.

X. Practitioner's Observation: The Impact of the Management Measures on the Industry

Ending: Risk Reminder

Note: This article is based on the "Management Measures for Human Assisted Reproductive Technology" (Ministry of Health Order No. 14, 2001) and current supporting standards. In case of policy updates, please refer to the latest documents from the National Health Commission.